The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial.
 
Alfred Witjes
Honoraria - Astellas Pharma; AstraZeneca; Beigene; Bristol-Myers Squibb/Pfizer; Ferring; Janssen; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD; Nucleix; Oncodiag; Sanofi/Aventis
 
Dean F. Bajorin
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Jürgen E. Gschwend
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb; Janssen-Cilag
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Janssen-Cilag
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ono Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Thierry Lebret
Speakers' Bureau - Bayer; Ipsen
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; MSD; Roche; VitaDx
 
Begoña Pérez-Valderrama
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; MSD Oncology; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer; Roche
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; Ipsen; MSD; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Pfizer (Inst); Roche (Inst)
 
Sandra Collette
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Joshua Zhang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Federico Nasroulah
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Shahrokh F. Shariat
Stock and Other Ownership Interests - Seagen; UroGen pharma
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Dr. Wolff Group; Ferring; Ipsen; Janssen; MSD; Olympus; Pfizer; Pierre Fabre; Roche; Sanochemia; Sanofi; UroGen pharma
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi
Research Funding - Astellas Pharma; Bayer; Sanofi
Patents, Royalties, Other Intellectual Property - Patent US07759077; Patent US20030054419; Patent US2003235816